Breast cancer｜司会・講師・ディスカッサントのご紹介

Breast cancer｜Discussion

解説【LBA4】Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase 3 KEYNOTE-522 study

吉波 哲大　Tetsuhiro Yoshinami
（大阪大学医学部附属病院 乳腺・内分泌外科／がんゲノム医療センター）

解説【LBA12】eMouvoir: Randomised phase 3 trial evaluating the impact of a personalized and remote Physical Activity (PA) for Breast Cancer Survivors (BCS). Results on the Quality of Life (QoL).

吉波 哲大　Tetsuhiro Yoshinami
（大阪大学医学部附属病院 乳腺・内分泌外科／がんゲノム医療センター）

解説【LBA18】Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ advanced/metastatic breast cancer (mBC) with or without brain metastases (BM): DESTINYBreast-12 primary results

下井 辰徳　Shimoi Tatsunori
（国立がん研究センター中央病院 腫瘍内科）

解説【LBA19】Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): the CAPItello-290 Phase 3 trial

下井 辰徳　Shimoi Tatsunori
（国立がん研究センター中央病院 腫瘍内科）

解説【LBA21】Human epidermal growth factor receptor 2 (HER2)-low and HER2-ultralow status determination in tumors of patients (pts) with hormone receptor–positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06)
【1816O】A multicentre, randomized, double-blind, placebo-controlled study of olanzapine-based triplet antiemetic therapy for prevention of delayed and persistent nausea and vomiting induced by trastuzumab deruxtecan in patients with metastatic breast cancer: ERICA study (WJOG14320B)

下井 辰徳　Shimoi Tatsunori
（国立がん研究センター中央病院 腫瘍内科）

解説【231O】Locoregional hypo vs normofractionated RT in early breast cancer: 5 years results of the HypoG-01 phase 3 UNICANCER trial

吉波 哲大　Tetsuhiro Yoshinami
（大阪大学医学部附属病院 乳腺・内分泌外科／がんゲノム医療センター）